The Netherlands facility is designed to handle a wide range of nanomedicines, including lipid-based nanoparticles
Category: News
The census found that 56% of people visit their GP for a UTI and 27% for thrush
The companies will focus on mechanisms of action, dose selection and biomarker analyses
First participant vaccinated in study of ovx836 booster dose
Therapy shows high efficacy in initial trial phase
First patient dosed in phase 1b trial of MB310 therapy
New long-term partnership to address neurological disorder treatments
Eco-friendly inhalers aim to reduce environmental impact
Insight into double-blind, phase i/ii clinical trial for oesophageal cancer
New treatment option approved for women in Scotland